Publication Name	World Journal of Gastroenterology
Manuscript ID	98827
Country	Spain

Received	2024-07-06 23:36
Peer-Review Started	2024-07-06 23:36
To Make the First Decision
Return for Revision	2024-08-10 01:31
Revised	2024-08-19 02:22
Second Decision	2024-08-22 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-08-22 06:08
Articles in Press	2024-08-22 06:08
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-08-30 21:30
Typeset the Manuscript	2024-09-05 00:12
Publish the Manuscript Online	2024-09-13 03:22

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management
Manuscript Source	Invited Manuscript
All Author List	Antonio M Caballero-Mateos and Guillermo Arturo Cañadas-de la Fuente
ORCID	Author(s) ORCID Number Antonio M Caballero-Mateos http://orcid.org/0000-0002-3425-7758 Guillermo Arturo Cañadas-de la Fuente http://orcid.org/0000-0002-3012-3410
Funding Agency and Grant Number
Corresponding Author	Antonio M Caballero-Mateos, PhD, Assistant Lecturer, Doctor, Doctor, Department of Gastroenterology and Hepatology, San Cecilio University Hospital, Granada, Spain, AV conocimiento sn, Granada 18014, Spain. ogy1492@hotmail.com
Key Words	Ulcerative colitis; Janus kinase inhibitor; Filgotinib; Tofacitinib; Upadacitinib
Core Tip	Janus kinase inhibitors such as Tofacitinib, Filgotinib, and Upadacitinib represent a significant advancement in ulcerative colitis management, offering effective induction and maintenance of remission, especially for patients unresponsive to conventional therapies. Despite potential safety concerns, these agents provide rapid action and the ability to tailor treatment to individual patient needs, marking a paradigm shift in ulcerative colitis treatment strategies.
Publish Date	2024-09-13 03:22
Citation	<p>Caballero-Mateos AM, Cañadas-de la Fuente GA. Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management. <i>World J Gastroenterol</i> 2024; 30(35): 3942-3953</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i35/3942.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i35.3942

Full Article (PDF)	WJG-30-3942-with-cover.pdf
Manuscript File	98827_Auto_Edited_010743.docx
Answering Reviewers	98827-answering-reviewers.pdf
Audio Core Tip	98827-audio.mp3
Conflict-of-Interest Disclosure Form	98827-conflict-of-interest-statement.pdf
Copyright License Agreement	98827-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	98827-non-native-speakers.pdf
Peer-review Report	98827-peer-reviews.pdf
Scientific Misconduct Check	98827-scientific-misconduct-check.png
Scientific Editor Work List	98827-scientific-editor-work-list.pdf
CrossCheck Report	98827-crosscheck-report.pdf